HCWB

HCW Biologics Inc.
CAPPED RATING

HCW Biologics Inc. (HCWB) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
B-
Factor Score 3.0 / 5.0
Growth
F
Factor Score 0.2 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
D-
Factor Score 0.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.6
EV / EBITDA -1.3
Rev Growth YoY N/M
Gross Margin 95.9%
Price Return 3M -70.6%
Price Return 12M -95.3%
Catalyst Signal 0.00
Market Cap $1.9M
TTM Revenue $6.7M
Price / Sales 0.3
ROE -151.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B- (3.0) F (0.2) C+ (2.6) D- (0.8) C+ (2.6) D+ (1.8)
2026-11-05 B- (3.0) F (0.3) C+ (2.6) D- (1.0) C+ (2.7) C- (1.9)
2026-10-29 B- (3.0) F (0.3) C+ (2.6) D- (1.0) C+ (2.7) C- (1.9)
2026-10-22 B- (3.0) F (0.3) C+ (2.6) D- (1.0) C+ (2.6) C- (1.9)
2026-10-15 B- (3.0) F (0.2) C+ (2.6) D- (1.0) C+ (2.6) C- (1.9)
Page 1 of 4